|
DK0915866T3
(da)
*
|
1996-07-29 |
2002-06-10 |
Warner Lambert Co |
Forbedret fremgangsmåde til syntese af beskyttende estere af (S)-3,4-dihydroxysmørsyre
|
|
KR100332703B1
(ko)
*
|
1998-07-24 |
2002-08-27 |
삼성정밀화학 주식회사 |
광학활성을갖는(s)-3,4-에폭시부티르산염의제조방법
|
|
CN1160468C
(zh)
*
|
1998-07-24 |
2004-08-04 |
三星精密化学株式会社 |
制备光学纯(s)-3,4-二羟基丁酸衍生物的方法
|
|
US6713290B2
(en)
|
1998-07-24 |
2004-03-30 |
Samsung Fine Chemicals Co., Ltd. |
Process for preparing optically pure (S)-3-hydroxy-γ-butyrolactone
|
|
US6235930B1
(en)
*
|
1999-03-31 |
2001-05-22 |
Board Of Trustees Operating Michigan State University |
Process for the preparation of 3,4-dihydroxybutanoic acid and derivatives thereof from substituted pentose sugars
|
|
HU227840B1
(en)
*
|
1999-05-06 |
2012-05-02 |
Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag |
Intermediates of atorvastatin synthesis and process for producing them
|
|
AU776613B2
(en)
|
1999-12-17 |
2004-09-16 |
Pfizer Science And Technology Ireland Limited |
A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt
|
|
CA2391357C
(en)
*
|
1999-12-17 |
2009-01-06 |
Warner Lambert Research And Development Ireland Limited |
A process for producing crystalline atorvastatin calcium
|
|
JP4598917B2
(ja)
*
|
2000-04-28 |
2010-12-15 |
ダイセル化学工業株式会社 |
ラクトンの製造方法
|
|
KR100645665B1
(ko)
|
2000-07-27 |
2006-11-13 |
에스케이 주식회사 |
(ｓ)-베타-하이드록시-감마-부티로락톤의 연속 제조방법
|
|
US6476235B2
(en)
*
|
2001-01-09 |
2002-11-05 |
Warner-Lambert Company |
Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
|
|
EP1728785A1
(en)
|
2001-01-09 |
2006-12-06 |
Warner-Lambert Company LLC |
7-[(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-heptanoic acid ester 3,5-dioxo-acetal
|
|
WO2002057229A1
(en)
*
|
2001-01-19 |
2002-07-25 |
Biocon India Limited |
FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
|
|
MXPA03010266A
(es)
*
|
2001-06-29 |
2004-03-10 |
Warner Lambert Co |
Formas cristalinas de la sal de calcio del acido [r-(r*, r*)]-2 -(4-fluorofenil)-¦, d-dihidroxi-5 -(1-metiletil)-3 -fenil-4- [(fenilamino) carbonil ]-1h- pirrol-1-heptanoico (2:1) (atorvastatin).
|
|
SK802004A3
(en)
*
|
2001-07-06 |
2004-10-05 |
Teva Pharma |
Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives
|
|
BR0215602A
(pt)
*
|
2002-02-25 |
2004-12-07 |
Biocon Ltd |
ésteres de boronato
|
|
GB0211716D0
(en)
|
2002-05-22 |
2002-07-03 |
Phoenix Chemicals Ltd |
Process
|
|
ATE368661T1
(de)
*
|
2002-08-06 |
2007-08-15 |
Warner Lambert Co |
Verfahren zur herstellung von 5-(4-fluorphenyl)-1- 2-((2r,4r)-4-hydroxy-6-oxo etrahydropyran-2- yl)ethylö-2-isopropyl-4-phenyl-1h-pyrrol-3- carbonsäurephenylamid
|
|
CA2499655A1
(en)
*
|
2002-09-18 |
2004-04-01 |
Sk Corporation |
Continuous process for the production of optically pure (s)-.beta.-hydroxy-.gamma.-butyrolactone
|
|
AU2003263031A1
(en)
*
|
2002-09-20 |
2004-04-08 |
Diversa Corporation |
Chemoenzymatic methods for the synthesis of statins and stain intermediates
|
|
US6713639B1
(en)
|
2002-10-28 |
2004-03-30 |
Council Of Scientific And Industrial Research |
Process for preparing enantiomerically pure (S)-3-hydroxy-gamma-butyrolactone
|
|
EP1615883A1
(en)
*
|
2003-04-14 |
2006-01-18 |
Warner-Lambert Company |
Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
|
|
US7232920B2
(en)
*
|
2003-04-22 |
2007-06-19 |
Biocon |
Process for stereoselective reduction of β-ketoesters
|
|
US7790197B2
(en)
*
|
2003-06-09 |
2010-09-07 |
Warner-Lambert Company Llc |
Pharmaceutical compositions of atorvastatin
|
|
US20040253305A1
(en)
*
|
2003-06-12 |
2004-12-16 |
Luner Paul E. |
Pharmaceutical compositions of atorvastatin
|
|
US7655692B2
(en)
*
|
2003-06-12 |
2010-02-02 |
Pfizer Inc. |
Process for forming amorphous atorvastatin
|
|
US20050271717A1
(en)
*
|
2003-06-12 |
2005-12-08 |
Alfred Berchielli |
Pharmaceutical compositions of atorvastatin
|
|
CN1852894A
(zh)
*
|
2003-09-17 |
2006-10-25 |
沃尼尔·朗伯有限责任公司 |
[R－(R*, R*)]－2－(4－氟苯基) －β,δ－二羟基－5－(1－甲基乙基) －3－苯基－4－[(苯基氨基)羰基] －1 H－吡咯－1－庚酸的结晶形式
|
|
WO2005068642A2
(en)
|
2003-10-01 |
2005-07-28 |
Board Of Trustees Operating Michigan State University |
Bacterial synthesis of 1,2,4-butanetriol enantiomers
|
|
CN1960972A
(zh)
*
|
2004-04-16 |
2007-05-09 |
辉瑞产品公司 |
用于形成无定形阿托伐它汀钙的方法
|
|
EP2540704B1
(en)
|
2004-05-05 |
2019-07-03 |
Pfizer Products Inc. |
Benethamine salt forms of atorvastatin
|
|
CA2754932C
(en)
|
2004-07-20 |
2014-04-01 |
Warner-Lambert Company Llc |
Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
|
|
WO2006046109A1
(en)
|
2004-10-28 |
2006-05-04 |
Warner-Lambert Company Llc |
Process for forming amorphous atorvastatin
|
|
US20090088465A1
(en)
*
|
2004-12-02 |
2009-04-02 |
Stephen Craig Dyar |
Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
|
|
DE602006013815D1
(de)
*
|
2005-05-31 |
2010-06-02 |
Kowa Co |
Verfahren zur herstellung von optisch aktiven ppar-aktivierenden verbindungen und zwischenprodukte für die herstellung
|
|
CA2547216A1
(en)
|
2005-09-21 |
2007-03-21 |
Renuka D. Reddy |
Process for annealing amorphous atorvastatin
|
|
DK1957452T3
(da)
*
|
2005-11-21 |
2010-07-26 |
Warner Lambert Co |
Nye former af [R-(R*,R*)]-2-(4-fluorphenyl)-B,B-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyre- magnesium
|
|
US20110165641A1
(en)
*
|
2006-03-31 |
2011-07-07 |
The Board Of Trustees Of Michigan State University |
Synthesis of 1,2,4-Butanetriol Enantiomers from Carbohydrates
|
|
CN101512004A
(zh)
*
|
2006-07-19 |
2009-08-19 |
密歇根州州立大学托管委员会 |
D-1,2,4-丁三醇的微生物合成
|
|
KR100850558B1
(ko)
|
2008-01-02 |
2008-08-06 |
조동옥 |
아토르바스타틴의 효율적인 제조방법
|
|
JP2009256316A
(ja)
|
2008-03-28 |
2009-11-05 |
Daicel Chem Ind Ltd |
β−ヒドロキシ−γ−ブチロラクトンの製造方法
|
|
CN101337906B
(zh)
*
|
2008-08-15 |
2012-06-27 |
河南豫辰精细化工有限公司 |
一种4-甲基-3-氧代-n-苯基戊酰胺的制备方法
|
|
EP2373609B1
(en)
|
2008-12-19 |
2013-10-16 |
KRKA, D.D., Novo Mesto |
Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
|
|
EP2327682A1
(en)
|
2009-10-29 |
2011-06-01 |
KRKA, D.D., Novo Mesto |
Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
|
|
MX2013015272A
(es)
|
2011-07-01 |
2014-04-14 |
Dsm Sinochem Pharm Nl Bv |
Cristales micronizados.
|
|
CN106397241A
(zh)
*
|
2016-08-23 |
2017-02-15 |
杨锋 |
一种4‑甲基‑3‑氧代‑n‑苯基戊酰胺的绿色环保后处理方法
|
|
CN106588689A
(zh)
*
|
2016-12-15 |
2017-04-26 |
河南豫辰药业股份有限公司 |
一种从结晶母液废液中回收阿托伐他汀中间体m4的方法
|
|
CN112939901B
(zh)
*
|
2021-02-09 |
2023-05-09 |
中国科学院福建物质结构研究所 |
一种α-羟基-γ-丁内酯的制备方法
|
|
CN114195670B
(zh)
*
|
2021-12-31 |
2024-03-15 |
河南豫辰药业股份有限公司 |
一种阿托伐他汀母核m4的精制方法
|
|
CN117447350A
(zh)
*
|
2023-10-26 |
2024-01-26 |
河南豫辰药业股份有限公司 |
一种阿托伐他汀m4有机废物综合再利用方法
|